Roche announced its definitive agreement to acquire Carmot Therapeutics, Inc., based in Berkeley, California, for an upfront purchase price of USD 2.7 billion, with additional milestone payments of up to USD 400 million.

Carmot Therapeutics’ Incretin Portfolio: A Boon for Obesity Treatment

The acquisition provides Roche access to Carmot Therapeutics’ innovative portfolio of incretins, which includes CT-388, CT-996, and CT-868, targeting the treatment of obesity in patients with and without type 2 diabetes, as well as type 1 diabetes patients.

CT-388 and Carmot’s Promising Clinical Stage Assets

CT-388, Carmot Therapeutics’ lead asset, is a Phase-2 ready dual GLP-1/GIP receptor agonist. The clinical data suggests its potential as a best-in-class treatment for obesity, offering differentiated efficacy and a unique profile for obesity management.

Impact on Healthcare: Roche’s Expansion into Obesity and Diabetes Care

This acquisition aligns with Roche’s commitment to improving care in obesity and related diseases. Thomas Schinecker, CEO of Roche Group, emphasizes the goal to enhance the standard of care and impact patients’ lives positively.

The transaction, subject to regulatory approvals, is expected to complete in the first quarter of 2024, significantly expanding Roche’s footprint in the healthcare industry.

  Berkeley, California, Carmot Therapeutics, obesity, Pharma acquisition news, Roche, Thomas Schinecker